New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 24, 2014
04:55 EDTEW, EW, EW, EW, EW, QDEL, QDEL, QDEL, QDEL, QDEL, SQNM, SQNM, SQNM, SQNM, SQNM, TNDM, TNDM, TNDM, TNDM, TNDM, VOLC, VOLC, VOLC, VOLC, VOLC, ATEC, ATEC, ATEC, ATEC, ATEC, CFN, CFN, CFN, CFN, CFN, ICUI, ICUI, ICUI, ICUI, ICUI, IART, IART, IART, IART, IART, ELGX, ELGX, ELGX, ELGX, ELGX, NUVA, NUVA, NUVA, NUVA, NUVAPiper Jaffray to hold a bus tour
7th Annual SoCal Medtech & Diagnostics Bus Tour to travel throughout San Diego on August 25-28.
News For EW;ELGX;IART;ICUI;CFN;ATEC;VOLC;TNDM;SQNM;QDEL;NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
09:56 EDTIARTIntegra deal with Tornier a win for both, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said he views Integra LifeSciences' (IART) acquisition of Tornier's (TRNX) U.S. ankle replacement and silastic toe replacement products as a "win win" for both companies. O'Brien estimates a deal price between $25M-$35M, saying he believes Integra gets a "quality total ankle system at an attractive price," while adding that Tornier clears the last hurdle with the FTC for its Wright Medical (WMGI) deal with the divestiture. O'Brien maintains his Overweight rating and $72 price target on Integra shares.
09:42 EDTEWLeerink medical supplies/devices analyst holds analyst/industry conference call
Medical Supplies & Devices Analyst Antalffy, along with St. Paul's Hospital & Vancouver General Hospital Cardiac Transplant Program Surgical Director, Dr. Anson Cheung, and San Rafaele Hospital Cardiac Catheterization Lab & Vascular Interventions, Dr. Antonio Colombo, assess Valtech's pipeline and potential market opportunity on an Analyst/Industry conference call to be held on September 3 at 12:30 pm.
09:36 EDTEWLeerink medical supplies/devices analyst holds analyst/industry conference call
Subscribe for More Information
05:34 EDTIARTIntegra LifeSciences to acquire Salto Talaris, Salto XT from Tornier
Subscribe for More Information
September 2, 2015
13:21 EDTEWHeartWare plunges after Valtech deal sparks downgrades
Shares of HeartWare (HTWR) have plunged after the company's acquisition of cardiac device maker Valtech, with multiple analysts struggling to find any particularly strong rationale for the deal. WHAT'S NEW: Raymond James' Jayson Bedford downgraded HeartWare to Market Perform from Outperform after the company announced Tuesday night that it agreed to acquire Valtech Cardio, an Israeli-based company focusing on heart valve devices. Bedford said he was "surprised" by the size of the deal, noting that the all-stock transaction is valued at roughly $430M and will see Valtech owning roughly 22% of HeartWare upon closing. The acquisition is simply not what Bedford "envisioned" for the company, said the analyst. His prior investment thesis was based upon HeartWare's potential to dominate the ventricular assist device market, an idea "validated" by St. Jude's (STJ) pending acquisition of Thoratec (THOR), said Bedford. That thesis has now been disrupted by last night's early-stage asset buy at a "steep price," raising the overall execution risk of HeartWare, the analyst tells investors. WHAT'S NOTABLE: HeartWare was also hit with a downgrade to Neutral by BTIG, with the research firm emphasizing that the transaction will bring significant dilution to the company's existing shareholders. Northland's Suraj Kalia was even more bearish this morning, saying that the acquisition "does not make sense," coming at an "astronomical" multiple for an asset with "no obvious complementarity" and different domain expertise. Valtech's Cardioband CE study involved just 45 patients and only 40% of those were followed up at twelve months, said Kalia, who contended that the study does not present an accurate picture of clinical viability. Heartware will have to invest "significantly" to get Valtech's technology through U.S. trials, said the analyst, and entering the transcatheter mitral valve repair market will also bring new competition in the form of Edwards (EW), Medtronic (MDT), Boston Scientific (BSX), St. Jude and Abbott (ABT). PRICE ACTION: Shares of HeartWare have dropped more than 19% in intraday trading to $65.98, dipping below their 52-week low in the process.
10:00 EDTQDELOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at H.C. Wainwright... Adobe (ADBE) initiated with a Perform at Oppenheimer... Antero Midstream (AM) initiated with a Buy at Ladenburg... Arbutus Biopharma (ABUS) initiated with an Outperform at JMP Securities... CSI Compressco (CCLP) initiated with a Market Perform at Wells Fargo... Cepheid (CPHD) initiated with an Equal Weight at Barclays... Cincinnati Financial (CINF) initiated with a Buy at MKM Partners... Disney (DIS) initiated with an Outperform at CLSA... Genomic Health (GHDX) initiated with an Underweight at Barclays... Green Brick (GRBK) initiated with a Neutral at Citi... Heron Therapeutics (HRTX) initiated with a Buy at BofA/Merrill... Karyopharm (KPTI) initiated with an Overweight at JPMorgan... PayPal (PYPL) initiated with a Buy at Argus... Quidel (QDEL) initiated with an Overweight at Barclays... Recro Pharma (REPH) initiated with a Buy at H.C. Wainwright.
09:17 EDTQDELBarclays life science analysts hold an analyst/industry conference call
Subscribe for More Information
07:05 EDTSQNMSequenom announces partnership with Perinatal Quality Foundation
Subscribe for More Information
05:28 EDTQDELQuidel initiated with an Overweight at Barclays
Target $28.
September 1, 2015
05:40 EDTNUVANuVasive to launch integrated global alignment platform at EUROSPINE
Subscribe for More Information
August 28, 2015
16:40 EDTSQNMSequenom files $300M mixed securities shelf
Subscribe for More Information
August 27, 2015
19:20 EDTCFNCareFusion issues recall for Alaris syringe pump
The FDA reported that an error in CareFusion's Alaris syringe pump model 8110 triggers a visual and audible alarm and causes the pump to stop supplying infusion to the patient. "Even when the user clears the error code... the syringe pump does not respond to key presses until the product is detached and reattached to the PC unit used to program, monitor and provide power to the syringe pump. Failure of syringe module may result in a delay or interruption of therapy and can lead to serious patient injury or death," said the report. CareFusion has received 108 reports of the issue occurring. There have been no reports of permanent injury or death. The firm informed customers of the problem in a July 20 letter and indicated the company will contact all affected customers within 60 days to schedule a repair. Reference Link
August 26, 2015
14:43 EDTQDELQuidel management to meet with William Blair
Subscribe for More Information
07:18 EDTIARTIntegra DFU study results positive in aggregate, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien stated after Integra LifeSciences' DFU data was published that some competitive products have better metrics in certain areas. However, all told, O'Brien views the results positively and expects Integra to have one of the best wound care portfolios in the market once this product is cleared and reimbursed sometime next year, he tells investors in a research note. The analyst kept an Overweight rating and $72 price target on Integra shares, which closed up 39c to $59.25 yesterday.
07:13 EDTIARTIntegra LifeSciences announces online publication of FOUNDER study results
Subscribe for More Information
August 25, 2015
17:32 EDTSQNMSequenom enters collaboration with UC San Diego Moores Cancer Center
Subscribe for More Information
07:29 EDTCFNBecton Dickinson acquisition positive, says Stifel
Subscribe for More Information
07:02 EDTNUVANuVasive exploring locations to build medical device facility
Subscribe for More Information
August 24, 2015
08:29 EDTQDEL, SQNM, NUVA, EW, TNDMWilliam Blair to hold a field trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use